Aging Is a Disease
chris.sol 🇬🇧@chrisdotsol
−3.6%
since Oct 6
The idea
I believe that by 2035 medicine starts treating aging itself as a treatable condition, not just the backdrop to disease. The core holds large pharma and GLP-1 leaders as ballast, with the real edge in clinical-stage drugs targeting age-related muscle, brain, and heart decline, plus diagnostics that catch disease early. A smaller slice sits in earlier-stage science like senolytics and gene editing for optionality, spread across many names rather than single bets, with a small cash buffer and a years-long horizon to let the thesis play out.
What it owns
- Drugs in human trials today target the brain and heart diseases that aging causes most, moving from symptom treatment to aging itself. · Alnylam PharmaceuticalsIts RNA-silencing platform turns off disease-causing genes, with biggest wins so far in heart and nerve diseases that aging drives., BiogenIt treats brain aging as a disease today with an Alzheimer's drug already approved, and stays while anti-amyloid treatment gains adoption., CytokineticsIt builds drugs for heart muscle that weakens or stiffens with age, treating organ-level decline directly as the take predicts medicine will do., BridgeBio PharmaIt sells a drug for ATTR, a protein-misfolding disease that mostly strikes aging hearts, making it one of the first paid for treating an aging process., Denali TherapeuticsIt builds drugs engineered to cross into the brain and slow the decline aging drives, advancing through trials on the same bet as competitors.27%
- The GLP-1 class already treats metabolic decline at scale; these companies anchor the basket while earlier-stage approaches mature. · Eli LillyIt sells the biggest proof so far that medicine can treat metabolic decline at scale, and holds its place as GLP-1 drugs expand into heart and kidney disease., Novo NordiskIt is the other GLP-1 leader with worldwide sales funding trials for aging-related conditions, and stays relevant if it remains a top-two player in metabolic medicine., AmgenIt rounds out the metabolic anchor with a different obesity mechanism than competitors, and stays relevant while its program advances through trials.23%
- Treating aging as a disease starts with catching damage early; these diagnostics screen for cancer and organ decline before symptoms appear. · GrailIts blood test screens for dozens of cancers before symptoms, catching age-related disease early enough to treat., NateraIts blood tests track organ health and monitor cancer, pushing surveillance testing as a way to act on decline before crisis sets in., Guardant HealthIt reads cancer from blood and screens people who feel fine yet, which is where aging-as-disease medicine starts., Tempus AIIt applies AI to medical records and genomes to spot age-related disease earlier and match it to treatment, depending on health system adoption.19%
- Senolytics, AI discovery and gene editing need years to mature but could pay substantially if aging biology yields to these tools. · BioAge LabsIts whole pipeline comes from mapping the biology of human aging itself, making it the purest expression of aging treated as a disease., Recursion PharmaceuticalsIt uses AI to find aging-related drug targets faster than traditional labs, paying off if the field moves quicker than expected., CRISPR TherapeuticsIt is the furthest-out piece: if age reversal means editing underlying biology, gene editing is the tool, and it already has an approved therapy.13%
- Weight loss and aging strip muscle; these drugs in trials now aim to preserve strength while treating metabolic disease. · Regeneron PharmaceuticalsIt is testing whether a muscle-preserving antibody paired with a GLP-1 beats weight loss alone for body composition, backed by a major pharma balance sheet., Scholar RockIt leads the second wave with a drug designed to preserve muscle, the tissue that weight loss and aging both strip away.12%
- Cash6%